Is MK-677 with ipamorelin legal in Australia?

Not one vial but one protocol: a daily oral secretagogue alongside an injected one. Both act at the same receptor, so this is a single mechanism delivered twice. MK-677 is the only component in the growth hormone section of this database with a two-year randomised trial, and that trial showed fat-free mass rose 1.1 kg against a 0.5 kg fall on placebo, with no significant strength or function benefit.

People run these together because one is convenient and slow and the other is injected and fast, and the combination feels like covering both. Pharmacologically it is one receptor, hit twice.

Mechanism: Both components are agonists at the growth hormone secretagogue receptor. MK-677 is orally bioavailable with a long enough duration to sustain raised growth hormone and IGF-1 across the day; ipamorelin is injected and short acting.

Regulatory history: Not approved. MK-677 completed clinical development without an approval and is sold as a research chemical; ipamorelin has never been approved.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for MK-677 with ipamorelin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.